Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2 - PubMed (original) (raw)
. 2005 Sep 1;116(3):359-67.
doi: 10.1002/ijc.21015.
Affiliations
- PMID: 15800944
- DOI: 10.1002/ijc.21015
Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2
Karianne E Longva et al. Int J Cancer. 2005.
Abstract
The anti-proliferative effect of the ErbB2 specific antibody Herceptin in cells overexpressing ErbB2 has previously been explained by endocytic downregulation of ErbB2. However, in the following, we demonstrate that Herceptin inhibited proliferation of ErbB2 overexpressing cells without downregulating ErbB2. Herceptin did also not induce endocytosis of ErbB2. Herceptin was found to blunt proliferation of SKBr3 cells overexpressing EGFR, ErbB2, and ErbB3 and expressing functional PTEN, probably by recruiting PTEN to the plasma membrane. Akt was found to be constitutively phosphorylated both in SKBr3 cells overexpressing EGFR, ErbB2 and ErbB3, and in SKOv3 cells, overexpressing EGFR and ErbB2. However, phosphorylation of Akt was inhibited by Herceptin only in SKBr3 cells. SKOv3 cells, which lack the tumour suppressor protein Ras homolog member I, was found to have constitutively phosphorylated mitogen activated protein kinase and functionally increased Ras activity. SKOv3 cells further had low expression levels of PTEN. We thus confirm that the anti-proliferative effect of Herceptin in SKBr3 cells is due to recruitment of PTEN to the plasma membrane and conclude that Herceptin does not blunt phosphatidyl inositol 3 kinase-induced growth in cells with constitutive Ras activity. We further conclude that endocytic downregulation of ErbB2 does not contribute to Herceptin's antiproliferative effect.
Similar articles
- Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Yakes FM, et al. Cancer Res. 2002 Jul 15;62(14):4132-41. Cancer Res. 2002. PMID: 12124352 - Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.
Nagy P, Jenei A, Damjanovich S, Jovin TM, Szölôsi J. Nagy P, et al. Pathol Oncol Res. 1999;5(4):255-71. doi: 10.1053/paor.1999.0255. Pathol Oncol Res. 1999. PMID: 10607920 Review. - Essential roles of Her2/erbB2 in cardiac development and function.
Negro A, Brar BK, Lee KF. Negro A, et al. Recent Prog Horm Res. 2004;59:1-12. doi: 10.1210/rp.59.1.1. Recent Prog Horm Res. 2004. PMID: 14749494 Review.
Cited by
- A Non-Canonical p75HER2 Signaling Pathway Underlying Trastuzumab Action and Resistance in Breast Cancer.
Nami B, Wang Z. Nami B, et al. Cells. 2024 Aug 29;13(17):1452. doi: 10.3390/cells13171452. Cells. 2024. PMID: 39273024 Free PMC article. - Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer.
Cho DH, Lee SK, Kim S, Choi MY, Jung SP, Lee J, Kim J, Koo MY, Bae SY, Kim JH, Kim JS, Ho KW, Lee JE, Nam SJ, Yang JH. Cho DH, et al. J Korean Surg Soc. 2013 May;84(5):273-80. doi: 10.4174/jkss.2013.84.5.273. Epub 2013 Apr 24. J Korean Surg Soc. 2013. PMID: 23646312 Free PMC article. - Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics-The Tale of HER2.
Leyton JV. Leyton JV. Antibodies (Basel). 2020 Jul 13;9(3):32. doi: 10.3390/antib9030032. Antibodies (Basel). 2020. PMID: 32668710 Free PMC article. Review. - The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer.
Dent S, Verma Sh, Latreille J, Rayson D, Clemons M, Mackey J, Verma S, Lemieux J, Provencher L, Chia S, Wang B, Pritchard K. Dent S, et al. Curr Oncol. 2009 Aug;16(4):25-35. doi: 10.3747/co.v16i4.469. Curr Oncol. 2009. PMID: 19672422 Free PMC article. - Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
Morse MA, Wei J, Hartman Z, Xia W, Ren XR, Lei G, Barry WT, Osada T, Hobeika AC, Peplinski S, Jiang H, Devi GR, Chen W, Spector N, Amalfitano A, Lyerly HK, Clay TM. Morse MA, et al. Int J Cancer. 2010 Jun 15;126(12):2893-903. doi: 10.1002/ijc.24995. Int J Cancer. 2010. PMID: 19856307 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous